The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate-Reference-Cited by-同舟云学术

The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

Published:2002-01 Issue:sup2 Volume:20 Page:45-54
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Lipton Allan,Small E.,Saad Fred,Gleason D.,Gordon David,Smith M.,Rosen Lee,Ortu Kowalski M.,Reitsma Dirk,Seaman John

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1081/CNV-120014886

Reference53 articles.

1. Skeletal complications of malignancy

2. Global cancer statistics

3. Spread of prostatic cancer to bone

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zoledronic acid: challenges and pitfalls amid rehabilitation in primary osteoporosis and beyond;Balneo and PRM Research Journal;2024-06-21

2. Combined chemotherapy of zoledronic acid and pamidronate in the treatment of bone metastases from nonsmall cell lung cancer and the effects on pain stress and bone metabolic indices;Drug Development Research;2024-01-24

3. Weight-Based Bisphosphonate Administration for Multiple Myeloma Patients and the Risks of Skeletal Complications;Journal of Clinical Medicine;2023-02-18

4. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Survey among Urologists in Switzerland, Germany, and Austria;Journal of Clinical Medicine;2023-01-13

5. Bone targeted new zoledronate derivative: design, synthesis, ^99mTc-coupling, in-silico study and preclinical evaluation for promising osteosarcoma therapy;International Journal of Radiation Biology;2022-05-11